Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new hope for relapsed/refractory MDS patients. The FDA has granted fast track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, combined with a hypomethylating agent (HMA) for high-risk myelodysplastic syndromes (MDS). Early phase 1b data showed a 45.5% overall response rate in heavily pretreated patients — a striking result given that fewer than 5% typically respond to HMA retreatment alone.
A new option on the horizon for relapsed/refractory MDS
The FDA has granted fast track designation to LYT-200 — a first-in-class anti-galectin-9 monoclonal antibody — in combination with a hypomethylating agent (HMA) for patients with relapsed/refractory (R/R) high-risk myelodysplastic syndromes (MDS). The designation comes alongside the completion of a successful end-of-phase 1 meeting with the FDA, signaling momentum toward a larger pivotal trial.
Phase 1b data from 11 efficacy-evaluable patients showed promising early results, with 18% of patients converting to transplant eligibility — a meaningful milestone in this difficult-to-treat population. The upcoming phase 2 STRIDE-MDS trial will enroll ~125 patients in a randomized, double-blind, placebo-controlled study.
By the Numbers
Why it matters: Patients with high-risk MDS who relapse after HMA therapy have very few options and poor outcomes. LYT-200's early efficacy signal, combined with a clean safety profile (no dose-limiting toxicities), positions it as a potentially practice-changing therapy for a broad patient population lacking actionable mutations.
